There is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.weiterlesen